Clinical trials: Obinutuzumab
Primary Membranous Nephropathy
OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)
This is a randomized, parallel group, active-controlled, open-label, Phase III study comparing the efficacy and safety of obinutuzumab versus cyclophosphamide combined with glucocorticoids in patients with primary membranous…
- Trial name
- NCT06781944
- Testing
- Obinutuzumab, CTX combined with Glucocorticoids
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Huashan Hospital
Chronic Lymphocytic Leukemia (CLL)
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL).
- Trial name
- AVO (NCT03580928)
- Testing
- Venetoclax, Obinutuzumab, Acalabrutinib
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD)…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04970901
- Testing
- Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab
- Where
- 40 sites in United States, Belgium and 4 more
- Volunteers
- 154 people
- Sponsor
- ADC Therapeutics S.A.
Mantle Cell Lymphoma, MCL
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma
- Trial name
- NCT06192888
- Testing
- Glofitamab, Obinutuzumab, Lenalidomide
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with obinutuzumab and how well this combination works in treating patients with low-grade non-Hodgkin lymphoma (NHL) that has…
- Conditions
- Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT01995669
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leucemia
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
The CLL2-BCG-trial is a prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of a debulking with bendamustine followed by an induction with GA101 (obinutuzumab) and…
- Trial name
- NCT02445131
- Testing
- Bendamustine, GA101, CAL-101
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- German CLL Study Group
CLL
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
A recent study showed that 6 cycles of obinutuzumab when given after at least 1 year of ibrutinib did result in MRD conversion in a significant proportion of patients (50%).
- Trial name
- NCT04639362
- Testing
- ibrutinib, venetoclax, obinutuzumab, ibrutinib, venetoclax
- Where
- 27 sites in Denmark, Netherlands
- Volunteers
- 85 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Non-Hodgkin's Lymphoma
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab…
- Trial name
- NCT01332968
- Testing
- Obinutuzumab, Cyclophosphamide, Doxorubicin
- Where
- 183 sites in United States, Australia and 16 more
- Volunteers
- 1,401 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphoid Leukemia
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in…
- Trial name
- CLL17 (NCT04608318)
- Testing
- Ibrutinib, Venetoclax, Obinutuzumab
- Where
- 181 sites in Austria, Belgium and 11 more
- Volunteers
- 897 people
- Sponsor
- German CLL Study Group
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT06849713
- Testing
- Zanubrutinib, Sonrotoclax, Obinutuzumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with atezolizumab administered after pretreatment with…
- Trial name
- NCT03866239
- Testing
- Obinutuzumab, Atezolizumab, Cibisatamab
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed…
- Trial name
- GLOBRYTE (NCT06084936)
- Testing
- Obinutuzumab, Glofitamab, Rituximab
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab)…
- Trial name
- CaDAnCe-303 (NCT06970743)
- Testing
- BGB-16673, Bendamustine, Rituximab
- Where
- 56 sites in China, Taiwan
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
Membranous Nephropathy
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
This is a non-pharmacological interventional monocentric study to primarily assess the levels of circulating phospholipase A2 receptor (PLA2R)-specific B cells in patients with PLA2R-mediated MN enrolled in the ORION and MONET…
- Trial name
- DEEPER (NCT06994468)
- Testing
- Flow-cytometry tetramer-based antigen-bait assay
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Chronic Lymphocytic Leukemia
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL.
- Trial name
- NCT02315768
- Testing
- GA101, Ibrutinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Diego
B-cell Lymphoma, Non Hodgkin Lymphoma
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.
- Conditions
- B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT05653271
- Testing
- Cyclophosphamide, Fludarabine, ACE1831
- Where
- 13 sites in United States, Hong Kong and 1 more
- Volunteers
- 16 people
- Sponsor
- Acepodia Biotech, Inc.
Lymphoma, Large B-Cell, Diffuse
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
The purpose of this study is to evaluate the clinical activity and tolerability of a combination of obinutuzumab plus venetoclax in patients with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT02987400
- Testing
- Venetoclax, Obinutuzumab
- Where
- 6 sites in Austria
- Volunteers
- 22 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Mantle Cell Lymphoma
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
This is a single arm, open label, national multicenter clinical study included patients with relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL), aiming to evaluate the efficacy of a chemotherapy free…
- Trial name
- NCT06324994
- Testing
- Linperlisib in combination with Obinutuzumab and Venetoclax
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Dalian Medical University
Mantle Cell Lymphoma
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
This is an open label, multicenter, fixed dose and dose escalation, phase I/II study. The study will be conducted in 3 steps. The first one (step A) will be to ensure the safety of the combination of Obinutuzumab (GA101) and…
- Trial name
- OAsIs (NCT02558816)
- Testing
- Ibrutinib + GA101 +GDC-0199
- Where
- 9 sites in France, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Nantes University Hospital
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in…
- Trial name
- AMPLIFY (NCT03836261)
- Testing
- Acalabrutinib, Venetoclax, Chemoimmunotherapy
- Where
- 169 sites in United States, Argentina and 25 more
- Volunteers
- 984 people
- Sponsor
- Acerta Pharma BV